CRISPR Stock Alpha and Beta Analysis


USD 63.28  3.62  5.41%   

This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as CRISPR Therapeutics AG. It also helps investors analyze the systematic and unsystematic risks associated with investing in CRISPR Therapeutics over a specified time horizon. Remember, high CRISPR Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation.
Continue to CRISPR Therapeutics Backtesting, CRISPR Therapeutics Valuation, CRISPR Therapeutics Correlation, CRISPR Therapeutics Hype Analysis, CRISPR Therapeutics Volatility, CRISPR Therapeutics History and analyze CRISPR Therapeutics Performance.
Please note that although CRISPR Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., DOW index.) So in this particular case, CRISPR Therapeutics did 0.43  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of CRISPR Therapeutics AG stock's relative risk over its benchmark. CRISPR Therapeutics has a beta of 1.65  . Let's try to break down what CRISPR's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CRISPR Therapeutics will likely underperform.
CRISPR Therapeutics Book Value per Share is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Book Value per Share of 31.59. As of 28th of June 2022, Enterprise Value over EBIT is likely to grow to 14.03, while Tangible Assets Book Value per Share are likely to drop 30.69.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.

CRISPR Therapeutics Quarterly Book Value per Share



CRISPR Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. CRISPR Therapeutics market risk premium is the additional return an investor will receive from holding CRISPR Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in CRISPR Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate CRISPR Therapeutics' performance over market.
α0.43   β1.65
90 days against DJI

CRISPR Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of CRISPR Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how CRISPR Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

CRISPR Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how CRISPR Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading CRISPR Therapeutics shares will generate the highest return on investment. By understating and applying CRISPR Therapeutics stock market price indicators, traders can identify CRISPR Therapeutics position entry and exit signals to maximize returns.

CRISPR Therapeutics Return and Market Media

The median price of CRISPR Therapeutics for the period between Wed, Mar 30, 2022 and Tue, Jun 28, 2022 is 58.96 with a coefficient of variation of 11.64. The daily time series for the period is distributed with a sample standard deviation of 6.88, arithmetic mean of 59.15, and mean deviation of 5.78. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
EPS Estimate03/31/2022
CRISPR Therapeutics 2022 AACR Annual Meeting - Marketscreene...04/11/2022
BB BIOTECH AG Increased investment level balanced by establi...04/21/2022
CRISPR Therapeutics shareholder returns have been solid, ear...05/05/2022
EPS Reported05/09/2022
CRISPR Therapeutics Sets New 52-Week Low Following Analyst D...05/11/2022
Financial Statements05/12/2022
Financial Statements05/16/2022
Why Orphan Drug Designation Offers Several Benefits - PR New...05/18/2022
Acquisition by Morrow Phuong Khanh of 90000 shares of CRISPR...05/24/2022
CRISPR Therapeutics to Host Innovation Day on June 21, 2022 ...05/31/2022
Acquisition by Fleming Harold Edward of 12000 shares of CRIS...06/10/2022
Unclassified Event06/13/2022
Financial Statements06/21/2022
Statistics on Global CRISPR Genome Editing Market Size Share...06/22/2022

About CRISPR Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all equity instruments such as Ford or other stocks, funds, and ETFs. Alpha measures the amount that position in CRISPR Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.

CRISPR Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of CRISPR Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CRISPR Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of CRISPR Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of CRISPR Therapeutics. Please utilize our Beneish M Score to check the likelihood of CRISPR Therapeutics' management manipulating its earnings.
Upcoming Quarterly Report15th of February 2022
Next Financial Report26th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End15th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Build Portfolio with CRISPR Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Continue to CRISPR Therapeutics Backtesting, CRISPR Therapeutics Valuation, CRISPR Therapeutics Correlation, CRISPR Therapeutics Hype Analysis, CRISPR Therapeutics Volatility, CRISPR Therapeutics History and analyze CRISPR Therapeutics Performance. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Transaction History
View history of all your transactions and understand their impact on performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
CRISPR Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of CRISPR Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of CRISPR Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...